What are the causes and recommended treatments for fatty liver disease?

Causes and Treatment of Fatty Liver Disease

Fatty liver disease (nonalcoholic fatty liver disease/NAFLD) is primarily caused by obesity, insulin resistance, and metabolic syndrome, and the cornerstone of treatment is achieving 7-10% body weight loss through dietary modification and exercise, with pioglitazone or vitamin E reserved for select patients with biopsy-proven steatohepatitis. 1, 2

Causes of Fatty Liver Disease

NAFLD affects 30-40% of adults in developed countries and represents the hepatic manifestation of metabolic syndrome 2. The primary risk factors include:

• Obesity (present in up to 90% of cases)
• Type 2 diabetes (present in ~50% of cases)
• Insulin resistance and metabolic syndrome
• Dyslipidemia and hypertension

Secondary Causes to Exclude

Before confirming NAFLD, rule out 3, 4:

• Significant alcohol consumption (>210 g/week in men, >140 g/week in women)
• Hepatitis C virus infection
• Medications: amiodarone, valproic acid, methotrexate, tamoxifen, corticosteroids, certain antiretrovirals
• Endocrine disorders: hypothyroidism, Cushing's syndrome
• Genetic conditions: Wilson's disease, hemochromatosis
• Nutritional disorders: celiac disease, severe malnutrition

Treatment Algorithm

Step 1: Lifestyle Modification (ALL Patients)

Weight Loss Targets 1, 5:

• 3-5% weight loss: Improves hepatic steatosis
• 7-10% weight loss: Required to improve inflammation and fibrosis (this is your primary goal)
• Achieve through 500+ kcal/day caloric deficit 6

Dietary Recommendations 7:

1. Follow Mediterranean diet pattern - the single most evidence-based dietary approach:

   • Daily: vegetables, fresh fruit, whole grains, legumes, nuts, extra virgin olive oil
   • Regular: fish and white meat
   • Minimal: red meat, processed meats, simple sugars, saturated fats

2. Eliminate/minimize:

   • Processed foods and fast food
   • Sugar-sweetened beverages and added fructose
   • Trans fats and saturated fatty acids
   • Commercial baked goods

3. Emphasize:

   • Monounsaturated fats (MUFAs) and polyunsaturated fats (PUFAs), especially omega-3 fatty acids
   • High-fiber foods: whole grains, vegetables, fruits, legumes
   • Plant-based proteins

Exercise Requirements 6, 5:

• Minimum: Moderate-intensity exercise ≥30 minutes, ≥3 times weekly
• Examples of moderate intensity: brisk walking, cycling, swimming, dancing
• Vigorous intensity (if tolerated): running, fast cycling, competitive sports
• Both aerobic and resistance exercise reduce liver fat; choose based on patient tolerance and preference

Alcohol Limits 7, 6:

• Maximum 1 drink/day for women, 2 drinks/day for men
• Even moderate consumption may worsen fibrosis progression; caution advised

Step 2: Risk Stratification for Pharmacotherapy

Only patients with biopsy-proven NASH or high-risk features warrant pharmacologic treatment 1, 2.

Refer for liver biopsy consideration if 5:

• Metabolic syndrome present
• Diabetes mellitus
• FIB-4 score suggests advanced fibrosis
• AST > ALT ratio
• Thrombocytopenia or other cirrhosis features

Step 3: Pharmacologic Treatment (Select Patients Only)

For Non-Diabetic Patients with Biopsy-Proven NASH 1, 2:

Vitamin E 800 IU/day:

• Improves steatosis, inflammation, and ballooning
• Caution: Avoid in patients with prostate cancer risk
• Evidence from PIVENS trial showing histologic improvement

For Patients with Biopsy-Proven NASH (With or Without Diabetes) 1, 2, 6:

Pioglitazone 30-45 mg/day:

• Improves steatosis, inflammation, ballooning, and shows trend toward fibrosis improvement
• Side effects: Weight gain (2-3 kg), fluid retention, bone fracture risk
• Monitor for contraindications (heart failure, bladder cancer history)

Step 4: What NOT to Use

Metformin 1, 5:

• Does NOT improve liver histology
• Not recommended as specific NAFLD treatment
• Safe to use for diabetes management in NAFLD patients, but don't expect liver benefit

Statins 2:

• Not indicated for NAFLD treatment specifically
• However, safe and should be used for cardiovascular risk management when indicated

Step 5: Advanced Disease Management

Refer for liver transplant evaluation if 2:

• Decompensated cirrhosis develops (ascites, encephalopathy, variceal bleeding)
• MELD score ≥10
• Hepatocellular carcinoma

Common Pitfalls to Avoid

1. Don't treat simple steatosis pharmacologically - reserve medications only for biopsy-proven NASH 1
2. Don't use metformin for liver disease - it doesn't work despite being an insulin sensitizer 1, 5
3. Don't focus on steatosis reduction alone - the real targets are inflammation and fibrosis 8
4. Don't ignore cardiovascular risk - this is the leading cause of death in NAFLD patients before cirrhosis develops 8
5. Don't recommend rapid weight loss - gradual sustained loss is more effective 7

Monitoring Strategy

• Low-risk patients (FIB-4 <1.3): Reassess fibrosis every 3-5 years 3
• Intermediate/high-risk patients: Annual monitoring with non-invasive fibrosis assessment
• All patients: Manage cardiovascular risk factors aggressively (lipids, blood pressure, glucose)

The evidence strongly supports that lifestyle modification achieving 7-10% weight loss is more effective than any pharmacologic therapy for the majority of NAFLD patients 1, 5. Medications should be reserved for the subset with proven steatohepatitis who are at highest risk for progression to cirrhosis.